LeonaBio Inc (LONA) Stock Analysis

AI analysis of LeonaBio Inc (LONA)

Hold

LeonaBio Inc is currently not a strong buy due to its low RSI of 34.945, indicating oversold conditions, and a significant year-to-date decline of 29.93%. The company is well-funded with a recent $90 million private placement, which supports its Phase 3 clinical trial for lasofoxifene, a promising treatment for breast cancer. However, the stock is trading at $4.73, well below its 52-week high of $14.21, suggesting potential for recovery but also highlighting significant risk. The main risk is its negative 20-day change of -15.23%, which reflects ongoing volatility and uncertainty in the biotech sector. Investors should consider holding their position until clearer signs of recovery emerge.

Valuation Metrics

The current forward P/E ratio for LeonaBio Inc (LONA) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E

Current P/E

0.00

Forward EV/EBITDA

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Forward P/S

5Y Average P/S

Current P/S

0.00

Whales holding LONA

T

TCG Crossover Management, LLC

+ HoldingLONA

+127.89%

3M Return

LONA FAQ — answered by Alphio AI

LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations. It operates in the Healthcare sector.

LeonaBio Inc is currently not a strong buy due to its low RSI of 34.945, indicating oversold conditions, and a significant year-to-date decline of 29.93%. The company is well-funded with a recent $90 million private placement, which supports its Phase 3 clinical trial for lasofoxifene, a promising treatment for breast cancer. However, the stock is trading at $4.73, well below its 52-week high of $14.21, suggesting potential for recovery but also highlighting significant risk. The main risk is its negative 20-day change of -15.23%, which reflects ongoing volatility and uncertainty in the biotech sector. Investors should consider holding their position until clearer signs of recovery emerge.